Benefits
Mood: Within-Group Change Only (One Trial)
In a 43-person trial in healthy adults, mood disturbance scores fell over two weeks while people took skullcap (p < 0.001) and did not change significantly while they took placebo (p = 0.072). That is a change from each person's own starting point. The published abstract reports no direct skullcap-versus-placebo comparison of mood, so it does not show the herb caused the change. Traditional Western herbalism uses the aerial parts as a relaxing nervine.
Anxiety: No Effect Versus Placebo in the Larger Trial
In the 43-person two-week trial, anxiety scores (Beck Anxiety Inventory) did not differ between skullcap and placebo (p = 0.191); most participants had little anxiety to begin with. An earlier 19-person single-dose study reported less self-rated anxiety than placebo, with more sedation at higher doses, but its abstract gives no statistics. No trial has tested skullcap in people with an anxiety disorder.
Self-Rated Sleep Quality (One Trial)
In a single-center crossover trial, 66 adults with mild to moderate primary insomnia took 400 mg/day of a branded extract (BlueCALM, supplied free by its maker EPO S.r.l.) or placebo for 8 weeks each. Self-rated sleep quality (PSQI) improved from 13.0 to 9.5 on skullcap and worsened from 11.5 to 13.3 on placebo, and sleep-diary measures such as total sleep time also favored skullcap. Sleep was self-reported only, scores stayed in the poor-sleep range, the effect carried over through the 28-day washout (so the placebo period was not a clean comparison), and the result has not been repeated.
Combinations Are Untested
Skullcap is often sold alongside ashwagandha, valerian, passionflower or magnesium, but no trial has tested it in combination with any of them for stress or sleep. Taking it with other sedating herbs may add to drowsiness.
Mechanism of action
GABA-A Receptor Binding (Lab and Animal Data)
Baicalin and baicalein, flavonoids present in American skullcap, bind to the benzodiazepine site of the GABA-A receptor in laboratory studies, work done largely with compounds from Chinese skullcap. Rats given oral American skullcap extract showed less anxiety-like behavior. No study has shown that these compounds reach the brain in active amounts after an oral dose in people.
Serotonin 5-HT7 Receptor Binding (Lab Data)
Hot-water and ethanol extracts of American skullcap blocked binding at serotonin 5-HT7 receptors in a test-tube assay, with scutellarin the most active isolated flavonoid. The concentrations involved were high, and no human study links this to mood or sleep.
Antioxidant Activity (Lab Data)
Skullcap aerial-parts extracts demonstrate measurable free-radical-scavenging activity in standard assays, attributable to scutellarin and related polyphenols. This is a laboratory finding; no antioxidant or nerve-protective effect has been measured in people.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial of 350 mg S. lateriflora three times daily versus placebo, each over two weeks, in 43 healthy volunteers. Outcomes: Beck Anxiety Inventory and global mood scales.
43 healthy adults; 81% were mildly anxious or less at baseline, and baseline anxiety differed between the randomized groups (p = 0.022).
Anxiety (Beck Anxiety Inventory) did not differ between skullcap and placebo (p = 0.191). Total Mood Disturbance fell from baseline during skullcap (p < 0.001) but not during placebo (p = 0.072); this is a within-treatment change, and no direct skullcap-versus-placebo comparison of mood is reported in the abstract. The authors note a carryover effect, low anxiety scores and a baseline imbalance that limit the findings.
Double-blind, placebo-controlled crossover study of single oral doses of organic freeze-dried S. lateriflora (100 mg, 200 mg and 350 mg) versus placebo, with self-rated anxiety, energy and cognition as outcomes. The published abstract itself gives no sample size, doses or statistics; these design details come from descriptions of the full paper.
19 healthy volunteers.
The authors reported noteworthy reductions in self-rated anxiety versus placebo, with more sedation at higher doses, but gave no statistics in the abstract. The study used single doses only and says nothing about daily use. The first author's listed affiliation is a company, Phytos Inc.
Single-center, randomized, double-blind, placebo-controlled crossover trial of 400 mg/day of an American skullcap aerial-parts extract (BlueCALM, standardized to 10% baicalin, supplied by its maker EPO S.r.l.) versus placebo, 56 days per period with a 28-day washout. Published in Nutrients, 2025.
66 adults aged 18 to 70 with mild to moderate primary insomnia.
Self-rated sleep quality (Pittsburgh Sleep Quality Index) improved from 13.0 to 9.5 during the extract period and worsened from 11.5 to 13.3 during placebo, and sleep-diary measures also favored the extract. No participant reported adverse effects. All outcomes were self-reported, scores stayed in the poor-sleep range, an effect carried over through the washout so the placebo period was not a clean comparison, and the result has not been repeated. It applies to this standardized extract, not to skullcap teas or tinctures in general.